# Anti-TGF-beta Therapy in Patients With Myelofibrosis

> **NCT01291784** · PHASE1 · TERMINATED · sponsor: **John Mascarenhas** · enrollment: 3 (actual)

## Conditions studied

- Myelofibrosis
- Primary Myelofibrosis
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- Post-essential Thrombocythemia Related Myelofibrosis

## Interventions

- **BIOLOGICAL:** monoclonal antibody to TGF-beta

## Key facts

- **NCT ID:** NCT01291784
- **Lead sponsor:** John Mascarenhas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Early termination when the drug was no longer made available by the pharmaceutical company due to unanticipated management and administrative decisions.
- **Last updated:** 2014-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01291784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01291784, "Anti-TGF-beta Therapy in Patients With Myelofibrosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01291784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*